冠状病毒RNA校对：分子基础与治疗靶点 - Suppr

Suppr

超能文献

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

作者信息

Robson Fran, Khan Khadija Shahed, Le Thi Khanh, Paris Clément, Demirbag Sinem, Barfuss Peter, Rocchi Palma, Ng Wai-Lung

出版信息

Mol Cell. 2020 Dec 17;80(6):1136-1138. doi: 10.1016/j.molcel.2020.11.048.

DOI:10.1016/j.molcel.2020.11.048

PMID:33338403

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833706/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ba5/7833706/cc042ac41f6a/gr2c_lrg.jpg

相似文献

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.冠状病毒RNA校对：分子基础与治疗靶点

Mol Cell. 2020 Dec 17;80(6):1136-1138. doi: 10.1016/j.molcel.2020.11.048.

Fitness Barriers Limit Reversion of a Proofreading-Deficient Coronavirus.健身障碍限制了校对缺陷型冠状病毒的逆转。

J Virol. 2019 Sep 30;93(20). doi: 10.1128/JVI.00711-19. Print 2019 Oct 15.

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA.冠状病毒 RNA 错配修复和利巴韦林切除的结构与分子基础。

Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E162-E171. doi: 10.1073/pnas.1718806115. Epub 2017 Dec 26.

A continuous assay for monitoring the synthetic and proofreading activities of multiple aminoacyl-tRNA synthetases for high-throughput drug discovery.用于高通量药物发现的多种氨酰-tRNA 合成酶的合成和校对活性的连续测定法。

RNA Biol. 2018;15(4-5):659-666. doi: 10.1080/15476286.2017.1397262. Epub 2017 Dec 15.

Specificity and catalysis hardwired at the RNA-protein interface in a translational proofreading enzyme.在一种翻译校对酶中，特异性和催化作用在RNA-蛋白质界面处紧密相连。

Nat Commun. 2015 Jun 26;6:7552. doi: 10.1038/ncomms8552.

Trigger loop of RNA polymerase is a positional, not acid-base, catalyst for both transcription and proofreading.RNA 聚合酶的触发环是转录和校对的位置而非酸碱催化剂。

Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5103-E5112. doi: 10.1073/pnas.1702383114. Epub 2017 Jun 12.

Experimental tests of two proofreading mechanisms for 5'-splice site selection.5'-剪接位点选择的两种校对机制的实验测试

ACS Chem Biol. 2006 Jun 20;1(5):316-24. doi: 10.1021/cb6001569.

RNA polymerase fidelity and transcriptional proofreading.RNA 聚合酶保真度和转录校读。

Curr Opin Struct Biol. 2009 Dec;19(6):732-9. doi: 10.1016/j.sbi.2009.10.009. Epub 2009 Nov 13.

On the evolution of accuracy and cost of proofreading tRNA aminoacylation.关于校正tRNA氨基酰化准确性和成本的演变

Proc Natl Acad Sci U S A. 1979 Sep;76(9):4507-10. doi: 10.1073/pnas.76.9.4507.

Synthetic evolutionary origin of a proofreading reverse transcriptase.一种校对逆转录酶的合成进化起源。

Science. 2016 Jun 24;352(6293):1590-3. doi: 10.1126/science.aaf5409.

引用本文的文献

A Comparison of Conserved Features in the Human Coronavirus Family Shows That Studies of Viruses Less Pathogenic than SARS-CoV-2, Such as HCoV-OC43, Are Good Model Systems for Elucidating Basic Mechanisms of Infection and Replication in Standard Laboratories.人类冠状病毒家族保守特征的比较表明，对致病性低于SARS-CoV-2的病毒（如HCoV-OC43）的研究是在标准实验室中阐明感染和复制基本机制的良好模型系统。

Viruses. 2025 Feb 13;17(2):256. doi: 10.3390/v17020256.

Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir.中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶中针对临床应用抑制剂奈玛特韦和恩西他韦耐药的关键残基研究。

Npj Viruses. 2024;2(1):23. doi: 10.1038/s44298-024-00028-2. Epub 2024 Jun 24.

Analysis of SARS-CoV-2 genome evolutionary patterns.分析 SARS-CoV-2 基因组的进化模式。

Microbiol Spectr. 2024 Feb 6;12(2):e0265423. doi: 10.1128/spectrum.02654-23. Epub 2024 Jan 10.

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence.口服莫努匹拉韦和奈玛特韦/利托那韦治疗新冠肺炎：一项侧重于真实世界证据的文献综述

Infect Dis Rep. 2023 Oct 25;15(6):662-678. doi: 10.3390/idr15060061.

MAb Targeting a Link Between ExoN and MTase of TGEV NSP14.单抗针对 TGEV NSP14 的 ExoN 和 MTase 之间的连接。

Monoclon Antib Immunodiagn Immunother. 2023 Oct;42(5):178-181. doi: 10.1089/mab.2023.0010. Epub 2023 Oct 19.

Emerging SARS-CoV-2 variants: Why, how, and what's next?新型严重急性呼吸综合征冠状病毒2变体：成因、方式及后续情况？

Cell Insight. 2022 May 2;1(3):100029. doi: 10.1016/j.cellin.2022.100029. eCollection 2022 Jun.

Viral Nucleases.病毒核酸酶

Viruses. 2023 Mar 13;15(3):740. doi: 10.3390/v15030740.

Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice.通过向小鼠鼻内接种表达匹配或不匹配刺突蛋白（S）的改良痘苗病毒安卡拉（MVA）来预防严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体。

NPJ Vaccines. 2023 Mar 27;8(1):47. doi: 10.1038/s41541-023-00645-7.

Whole-Genome Comparison of Representatives of All Variants of SARS-CoV-2, Including Subvariant BA.2 and the GKA Clade.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）所有变体代表的全基因组比较，包括BA.2亚变体和GKA进化枝。

Adv Virol. 2023 Mar 9;2023:6476626. doi: 10.1155/2023/6476626. eCollection 2023.

Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.通过基于残基能量分解的药效团建模、分子对接和分子动力学模拟鉴定 SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶的非核苷抑制剂。

J Infect Public Health. 2023 Apr;16(4):501-519. doi: 10.1016/j.jiph.2023.02.009. Epub 2023 Feb 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验